Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial John Marsden, Mike Kelleher, Eil…

CHARACTERISTICS, TREATMENT PATTERNS AND RETENTION WITH EXTENDED-RELEASE SUBCUTANEOUS BUPRENORPHINE FOR OPIOID USE DISORDER: A POPULATION-BASED COHORT STUDY IN ONTARIO, CANADA Iacono A, Wang T, Tadrous M, Campbell 1, Kolla 8, Leece P, Sproule B, Kl…

A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder.  Miller JC, Brooks MA, Wurzel KE, Cox EJ, Wurzel JF 3rd.  Drugs R D. 2023 Dec;23(4):339-362. doi: 10.1007/s40268-023-00443-5. Epub 2023 No…

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder.  Wipper B, Cooke MP, Winkelman JW.  Nat Sci Sleep. 2023 Oct 21;15:851-859. doi: 10.2147/NSS.S427403. PMID…

An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results,  K Aaron Geno, Adina Badea, Kara L Lynch, Paul Jannetto, Jacqueline A Hubbard, Robert D Nerenz, Mark A Cervinski,  The Jou…

Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.  Mariani, JJ, Dobbins, RL, Heath, A, Gray, F, Hassman, H.  Am J Addict. 2023; 1…